Search
Chronic Lymphocytic Leukemia Clinical Trials
A listing of 67 Chronic Lymphocytic Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
37 - 48 of 67
There are currently 67 active clinical trials seeking participants for Chronic Lymphocytic Leukemia research studies. The states with the highest number of trials for Chronic Lymphocytic Leukemia participants are California, Ohio, Illinois and Michigan.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Recruiting
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back or has not gone away after treatment.
The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research study combines two different ways of fighting disease, antibodies and T cells, hoping... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
01/08/2025
Locations: Houston Methodist Hospital, Houston, Texas +1 locations
Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation
Recruiting
This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT).
The names of the study drugs involved in this research study are:
* Glofitamab (a T-cell bispecific humanized monoclonal antibody)
* Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody)
* Polatuzumab vedotin (an antibody-drug conju... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +3 locations
Conditions: Chronic Lymphocytic Leukemia, Richter's Transformation
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Recruiting
Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Chronic Lymphocytic Leukemia
Pirtobrutinib and Venetoclax with MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Recruiting
This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study also seeks to adopt a blood test which shows a small number of cancer cells in the body after cancer treatment called minimal residual disease as a guide to determine length of treatment. Drugs used in chemotherapy, such as pirtobrutinib and venetoclax, work in different ways to stop the growth of tumor cells, either by killing th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are:
* Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant?
* Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Mayo Clinic Arizona, Phoenix, Arizona +23 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruiting
This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition in which chronic lymphocytic leukemia or small lymphocytic lymphoma changes into a fast-growing type of lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax is in a class of medications ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
Recruiting
Metabolic reprogramming has been identified as a hallmark of cancer. Almost a century after Otto Warburg initially discovered increased glycolytic activity in tumor tissue ("Warburg effect"), therapeutic targeting of cancer metabolism has become a field of intense research effort in cancer biology.
A growing appreciation of metabolic heterogeneity and complexity is currently reshaping investigators "simplistic" understanding of metabolic reprogramming in cancer. Discovering metabolic vulnerabil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Chronic Lymphocytic Leukemia
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Recruiting
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).
Gender:
ALL
Ages:
55 years and below
Trial Updated:
11/01/2024
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Recruiting
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following:
Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT0509... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/30/2024
Locations: Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Recruiting
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: UC Irvine Health, Orange, California +8 locations
Conditions: B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Recruiting
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until end of treatment, then followed for 52 weeks or until disease progression or discontinuation due to toxicity or death. After completion of the 52... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Mount Sinai- Icahn School of Medicine, New York, New York +3 locations
Conditions: Richter Syndrome, Chronic Lymphocytic Leukemia
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Recruiting
This is a single center, open-label, phase II study of venetoclax (ABT-199) added to ibrutinib or acalabrutinib in patients with high-risk CLL who have received at least 12 months of ibrutinib or acalabrutinib monotherapy.
The study will estimate the therapeutic efficacy of venetoclax consolidation in patients who have detectable CLL after receiving ibrutinib or acalabrutinib for at least 12 months and who have high risk CLL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia
37 - 48 of 67